omecamtiv mecarbil profile

ID Source	ID
PubMed CID	11689883
CHEMBL ID	1800955
CHEBI ID	188664
SCHEMBL ID	400544
MeSH ID	M0543834

Synonym
HY-14233
methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate
amg-423
omecamtiv mecarbil ,
ck-452
ck-1827452
methyl 4-[[2-luoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate
873697-71-3
CHEBI:188664
CHEMBL1800955 ,
D09648
omecamtiv mecarbil (usan/inn)
omecamtiv mecarbil [usan:inn]
methyl 4-((2-fluoro-3-(((6-methylpyridin-3-yl)carbamoyl)amino)phenyl)methyl) piperazine-1-carboxylate
unii-2m19539erk
2m19539erk ,
1-piperazinecarboxylic acid, 4-((2-fluoro-3-((((6-methyl-3-pyridinyl)amino)carbonyl)amino)phenyl)methyl)-, methyl ester
ck 1827452
bdbm50348423
methyl 4-(2-fluoro-3-(3-(6-methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate
BCP9001023
methyl 4-[(2-fluoro-3-{[(6-methylpyridin-3-yl)carbamoyl]amino}phenyl)methyl]piperazine-1-carboxylate
BCPP000140
BCP0726000250
omecamtiv mecarbil (ck-1827452)
NCGC00346618-01
CS-0460
omecamtiv mecarbil [usan]
omecamtiv mecarbil [who-dd]
omecamtiv mecarbil [inn]
S2623
amg 423
gtpl8740
smr004703017
MLS006011266
SCHEMBL400544
methyl 4-[[2-fluoro-3-[n'-(6-methylpyridin-3-yl)ureido]phenyl]methyl]piperazine-1-carboxylate
ck1827452
methyl 4-(2-fluoro-3-{[(6-methylpyridin-3-yl)carbamoyl]amino}benzyl)piperazine-1-carboxylate
AC-32748
AKOS026674125
J-690376
EX-A714
ck-1827452;omecamtiv mecarbil
HMS3656F05
mfcd18633260
AS-60560
NCGC00346618-07
RFUBTTPMWSKEIW-UHFFFAOYSA-N
SW219490-1
DB11816
omecamtiv mercarbil
FT-0700389
F15273
omecamtiv mecarbil;ck-1827452;ck 1827452
BCP03048
Q7089956
SB16684
omecamtiv-mecarbil
CCG-268662
NCGC00346618-02
DTXSID901025949

Excerpt	Reference	Relevance
"Omecamtiv mecarbil is a small molecule that has been shown to improve cardiac function in patients with heart failure (HF) with reduced ejection fraction and is currently being developed as an oral modified release tablet for subjects with chronic HF. "	( Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction. Ahamadi, M; Chen, PW; Dutta, S; Lee, E; Trivedi, A, 2022)	2.43
"Omecamtiv mecarbil (OM) is a selective small molecule activator of cardiac myosin that prolongs myocardial systole and increases stroke volume without apparent effects on myocardial oxygen demand."	( Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model. Chen, WJ; Huang, CH; Tsai, MS; Wu, SN, 2022)	2.89
"Omecamtiv mecarbil is a well-tolerated drug in heart failure patients. "	( Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis. Alqatati, F; Bugazia, S; Elbahnasawy, M; Elsayed, SM; Elsnhory, AB; Fathy, MA; Nourelden, AZ; Ragab, KM; Shehata, M, )	1.88
"Omecamtiv mecarbil (OM) is a positive inotrope that is thought to bind directly to an allosteric site of the β-cardiac myosin. "	( Insights into the Mechanism of the Cardiac Drug Omecamtiv Mecarbil─A Computational Study. Chakraborti, A; Schwartz, SD; Tardiff, JC, 2022)	2.42
"Omecamtiv mecarbil (OM) is a direct myosin activator that augments left ventricular systolic function. "	( KCCQ total symptom score, clinical outcome measures, and adverse events associated with omecamtiv mecarbil for heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Ibrahim, R; Khludenev, G; Olagunju, A; Takamatsu, C; Terrani, K; William, P, 2023)	2.58
"Omecamtiv mecarbil is a novel, selective cardiac myosin activator that has been shown to improve cardiac function and to decrease ventricular volumes, heart rate, and N-terminal pro-B-type natriuretic peptide in patients with chronic HF."	( Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. Büchele, G; Diaz, R; Felker, GM; Honarpour, N; Kurtz, CE; Legg, JC; Malik, FI; McMurray, JJV; Metra, M; Solomon, SD; Teerlink, JR; Varin, C, 2020)	2.72
"Omecamtiv mecarbil (OM) is a putative positive inotropic tool for treatment of systolic heart dysfunction, based on the finding that in vivo it increases the ejection fraction and in vitro it prolongs the actin-bond life time of the cardiac and slow-skeletal muscle isoforms of myosin. "	( Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil. Caremani, M; Gallart, C; Governali, S; Linari, M; Lombardi, V; Ottenheijm, C; Pertici, I; Piazzesi, G; Stienen, G, 2020)	2.22
"Omecamtiv mecarbil (OM) is a selective cardiac myosin activator (myotrope), currently in Phase 3 clinical investigation as a novel treatment for heart failure with reduced ejection fraction. "	( Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model. Gao, B; Qu, Y; Sutherland, W; Vargas, HM, 2020)	2.39
"Omecamtiv mecarbil (OM) is a novel medicine for systolic heart failure, targeting myosin to enhance cardiomyocyte performance. "	( Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline. Beard, N; Chan, W; Cheesman, E; Dashwood, A; Haqqani, H; Hay, K; Molenaar, P; Spratt, M; Wong, YW, 2021)	2.45
"Omecamtiv mecarbil (OM) is a myosin activator (myotrope), developed as a potential therapeutic agent for heart failure with reduced ejection fraction. "	( Comprehensive in vitro pro-arrhythmic assays demonstrate that omecamtiv mecarbil has low pro-arrhythmic risk. Arimura, Z; Fang, M; Gao, B; Qu, Y; Vargas, HM, 2021)	2.3
"Omecamtiv mecarbil (OM) is a novel cardiac myosin activator that is currently in clinical development for the treatment of heart failure. "	( Pharmacokinetics, Disposition, and Biotransformation of [ Dutta, S; Lee, E; Mackowski, M; Trivedi, A; Wahlstrom, J, 2021)	2.06
"Omecamtiv mecarbil (OM) is a cardiac myosin activator in clinical development for the treatment of heart failure. "	( Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator. Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Mackowski, M; Oberoi, RK; Simiens, MA; Terminello, B; Trivedi, A; Zhang, H, 2021)	2.28
"Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure with reduced ejection fraction. "	( Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects. Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Oberoi, RK; Spring, M; Trivedi, A; Zhang, H, 2021)	2.47
"Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction. "	( Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv Mecarbil. Abbasi, S; Dutta, S; Flach, S; Hutton, S; Jafarinasabian, P; Lee, E; Mackowski, M; Oberoi, RK; Trivedi, A; Zhang, H, 2021)	2.29
"Omecamtiv mecarbil (OM) is a cardiac myosin activator under clinical development for the treatment of heart failure. "	( Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects. Bhatia, A; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Mackowski, M; Terminello, B; Trivedi, A; Zhang, H, 2021)	2.36
"Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure. "	( Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations. Abbasi, S; Brooks, A; Darpo, B; Dutta, S; Flach, S; Hsu, CP; Israel, S; Jafarinasabian, P; Lee, E; Terminello, B; Trivedi, A; Xue, H; Zhang, H, 2022)	3.61
"Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. "	( Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects. Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Malik, FI; Trivedi, A; Zhang, H, 2022)	2.38
"Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure (HF) with reduced ejection fraction. "	( Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects. Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Sohn, W; Terminello, B; Trivedi, A; Zhang, H, 2022)	2.42
"Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. "	( Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects. Abbasi, S; Aoki, M; Dutta, S; Hutton, S; Lee, E; Mackowski, M; Malik, FI; Trivedi, A, 2021)	2.3
"Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. "	( Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model. Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Kulkarni, P; Lee, E; Sohn, W; Spring, M; Trivedi, A; Wahlstrom, J; Zhang, H, 2021)	2.31
"Omecamtiv mecarbil is a selective, small-molecule activator of cardiac myosin that is being developed as a potential treatment for heart failure with reduced ejection fraction. "	( Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Hartman, JJ; Houdusse, A; Malik, FI; Planelles-Herrero, VJ; Robert-Paganin, J, 2017)	2.12
"Omecamtiv mecarbil (OM) is a pharmacological agent that augments cardiac contractile function by enhancing myofilament Ca"	( Omecamtiv Mecarbil Abolishes Length-Mediated Increase in Guinea Pig Cardiac Myofiber Ca Chandra, M; Gollapudi, SK; Reda, SM, 2017)	3.34
"Omecamtiv mecarbil (OM) is a myosin activator agent developed for the treatment of heart failure. "	( Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes. Almássy, J; Bányász, T; Horváth, B; Magyar, J; Nánási, PP; Papp, Z; Szentandrássy, N; Tóth, A; Veress, R, 2017)	2.18
"Omecamtiv mecarbil (OM) is a positive cardiac inotrope in phase-3 clinical trials for treatment of heart failure. "	( Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke. Barua, B; Goldman, YE; Greenberg, MJ; Ostap, EM; Winkelmann, DA; Woody, MS, 2018)	2.22
"Omecamtiv mecarbil (OM) is a compound that has been developed to treat systolic heart failure via targeting the cardiac myosin heavy chain to increase myocardial contractility."	( Omecamtiv Mecarbil Slows Myosin Kinetics in Skinned Rat Myocardium at Physiological Temperature. Awinda, PO; Kieu, TT; Tanner, BCW, 2019)	2.68
"Omecamtiv mecarbil is a selective cardiac myosin activator that augments cardiac contractility in patients with systolic heart failure through a dose-dependent increase in systolic ejection time."	( Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. Chen, MM; Chou, W; Eisenberg, P; Escandón, R; Greenberg, BH; Lee, JH; Malik, FI; Megreladze, I; Saikali, KG; Shaburishvili, T; Treshkur, T; Wasserman, SM; Wolff, AA, 2015)	2.16
"Omecamtiv mecarbil (OM) is a novel inotropic agent that prolongs systolic ejection time and increases ejection fraction through myosin ATPase activation. "	( Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity. Aasum, E; Bakkehaug, JP; Boardman, N; Engstad, ET; How, OJ; Kildal, AB; Larsen, TS; Myrmel, T; Næsheim, T; Rønning, L, 2015)	2.2
"Omecamtiv mecarbil is a promising new inotropic agent developed for heart failure that may circumvent such limitations."	( Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K. Li, BH; Ryba, DM; Solaro, RJ; Utter, MS; Wolska, BM, 2015)	2.58
"Omecamtiv Mecarbil (OM) is a small molecule allosteric effector of cardiac myosin that is in clinical trials for treatment of systolic heart failure. "	( Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity. Forgacs, E; Miller, MT; Stock, AM; Winkelmann, DA, 2015)	1.86
"Omecamtiv mecarbil is a novel small molecule that directly activates cardiac myosin and increases cardiac contractility without increasing cardiac myocyte intracellular calcium. "	( Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Alvarez, P; Banfield, C; Johnson, J; Malik, F; Monsalvo, ML; Palaparthy, R; Smith, B; Yan, L, 2016)	2.1
"Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function in healthy volunteers and in patients with chronic heart failure."	( Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. Cleland, JGF; Dickstein, K; Ezekowitz, JA; Felker, GM; Filippatos, GS; Kim, JB; Knusel, B; Lei, L; Malik, FI; McMurray, JJV; Metra, M; Ponikowski, P; Teerlink, JR; Wasserman, SM; Wolff, AA, 2016)	2.2
"Omecamtiv mecarbil (OM) is a myosin activator agent recently developed for treatment of heart failure. "	( Dose-dependent electrophysiological effects of the myosin activator omecamtiv mecarbil in canine ventricular cardiomyocytes. Banyasz, T; Horvath, B; Kistamas, K; Magyar, J; Masuda, L; Nanasi, PP; Papp, Z; Szentandrassy, N; Vaczi, K, 2016)	2.11

Excerpt	Reference	Relevance
"Omecamtiv mecarbil has a clearance of 11.7 L/h (0.701% relative standard error) and a central volume distribution of 275 L (2.12% relative standard error)."	( Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction. Ahamadi, M; Chen, PW; Dutta, S; Lee, E; Trivedi, A, 2022)	1.71

Excerpt	Reference	Relevance
" An ideal inotropic drug should restore effective tissue perfusion by enhancing myocardial contractility without causing adverse effects."	( Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? Campia, U; Gheorghiade, M; Nodari, S, 2010)	0.36
" No dose-dependent differences emerged in the proportion of patients stopping ETT3 for any reason or in the pattern of adverse events."	( Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. Chen, MM; Chou, W; Eisenberg, P; Escandón, R; Greenberg, BH; Lee, JH; Malik, FI; Megreladze, I; Saikali, KG; Shaburishvili, T; Treshkur, T; Wasserman, SM; Wolff, AA, 2015)	0.71
" Pooled analysis showed that omecamtiv mecarbil is not associated with increased incidence of death, any adverse events, hypotension, heart failure, ventricular tachyarrhythmia, dyspnea, dizziness, and serious adverse events."	( Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis. Alqatati, F; Bugazia, S; Elbahnasawy, M; Elsayed, SM; Elsnhory, AB; Fathy, MA; Nourelden, AZ; Ragab, KM; Shehata, M, )	0.73
" This review compares OM to placebo by evaluating its effect on clinical outcomes and adverse events in patients with heart failure with reduced left ventricular ejection fraction."	( KCCQ total symptom score, clinical outcome measures, and adverse events associated with omecamtiv mecarbil for heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Ibrahim, R; Khludenev, G; Olagunju, A; Takamatsu, C; Terrani, K; William, P, 2023)	1.13

Excerpt	Reference	Relevance
" Pharmacokinetic and safety data were analyzed from 62 and 63 subjects in the fasting and fed states, respectively."	( Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Alvarez, P; Banfield, C; Johnson, J; Malik, F; Monsalvo, ML; Palaparthy, R; Smith, B; Yan, L, 2016)	0.66
" Coadministration of OM with omeprazole was not associated with any clinically significant pharmacokinetic drug interactions."	( Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects. Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Sohn, W; Terminello, B; Trivedi, A; Zhang, H, 2022)	0.98
" The potential for a pharmacokinetic (PK) drug-drug interaction (DDI) was investigated, specifically to determine whether a single 50 mg dose of OM would impact the PKs of a single 10 mg dose of rosuvastatin in an open-label study in 14 healthy subjects."	( Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model. Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Kulkarni, P; Lee, E; Sohn, W; Spring, M; Trivedi, A; Wahlstrom, J; Zhang, H, 2021)	0.87
" In conclusion, OM coadministered with digoxin or amiodarone did not result in any clinically relevant pharmacokinetic drug-drug interactions."	( Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects. Abbasi, S; Dutta, S; Flach, S; Hsu, CP; Hutton, S; Jafarinasabian, P; Lee, E; Sohn, W; Trivedi, A; Zhang, H, 2022)	0.98
" The objectives of this study were to analyze the pharmacokinetic (PK) properties of omecamtiv mecarbil and to investigate the effects of potential covariates on pertinent PK parameters using population PK modeling of data from 3 clinical trials in healthy subjects (n = 85) and 3 clinical trials in patients with HF (n = 4261)."	( Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction. Ahamadi, M; Chen, PW; Dutta, S; Lee, E; Trivedi, A, 2022)	1.21

Excerpt	Reference	Relevance
" The potential for a pharmacokinetic (PK) drug-drug interaction (DDI) was investigated, specifically to determine whether a single 50 mg dose of OM would impact the PKs of a single 10 mg dose of rosuvastatin in an open-label study in 14 healthy subjects."	( Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model. Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Kulkarni, P; Lee, E; Sohn, W; Spring, M; Trivedi, A; Wahlstrom, J; Zhang, H, 2021)	0.87
" In vitro studies demonstrate OM as a substrate and inhibitor of P-glycoprotein (P-gp), which can result in drug-drug interactions."	( Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects. Abbasi, S; Dutta, S; Flach, S; Hsu, CP; Hutton, S; Jafarinasabian, P; Lee, E; Sohn, W; Trivedi, A; Zhang, H, 2022)	0.98

Excerpt	Reference	Relevance
"62 hours, and absolute bioavailability was estimated as 90%; elimination half-life was approximately 18."	( Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. Chow, AT; Ma, P; Malik, FI; Vu, T; Wang, YM; Xiao, JJ, 2015)	0.66
" The relative bioavailability was high (> 75%) for three MR formulations but lower (< 65%) for the other two."	( Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Alvarez, P; Banfield, C; Johnson, J; Malik, F; Monsalvo, ML; Palaparthy, R; Smith, B; Yan, L, 2016)	0.66
"The relative bioavailability of omecamtiv mecarbil was high (> 75%) for 3 of the five MR formulations."	( Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Alvarez, P; Banfield, C; Johnson, J; Malik, F; Monsalvo, ML; Palaparthy, R; Smith, B; Yan, L, 2016)	0.94
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"5 mg OM MR tablets and to assess its relative bioavailability to the 25 mg MR tablet, a 25 mg oral solution under fed or fasted states in Study 2 (n = 34)."	( Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator. Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Mackowski, M; Oberoi, RK; Simiens, MA; Terminello, B; Trivedi, A; Zhang, H, 2021)	0.84
" The primary objective of this study was to determine the bioavailability of the minitablets relative to the adult matrix MR formulation tablets."	( Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects. Bhatia, A; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Mackowski, M; Terminello, B; Trivedi, A; Zhang, H, 2021)	0.92
"Relative bioavailability of slow-release minitablets was demonstrated to be similar to the adult matrix MR formulation."	( Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects. Bhatia, A; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Mackowski, M; Terminello, B; Trivedi, A; Zhang, H, 2021)	0.92
"Study 1 (n = 36) evaluated the bioavailability and pharmacokinetics after intravenous infusion (15 mg/h for 4 h) and an oral modified release (MR) tablet in healthy Japanese and Caucasian subjects using 25 mg single and multiple doses and 50 mg single dose."	( Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects. Abbasi, S; Aoki, M; Dutta, S; Hutton, S; Lee, E; Mackowski, M; Malik, FI; Trivedi, A, 2021)	0.86

Excerpt	Relevance	Reference
" New insight has been gained regarding volume management, including dosing strategies for intravenous loop diuretics and the role of ultrafiltration in patients with heart failure and renal dysfunction."	( Acute decompensated heart failure: update on new and emerging evidence and directions for future research. Albert, NM; Butler, J; Carson, PE; Collins, SP; Colvin-Adams, M; Dimarco, JP; Ezekowitz, JA; Fang, JC; Givertz, MM; Hernandez, AF; Hershberger, RE; Katz, SD; Krishnamani, R; Rogers, JG; Spertus, JA; Starling, RC; Stevenson, WG; Stough, WG; Sweitzer, NK; Tang, WH; Teerlink, JR; Walsh, MN; Westlake Canary, CA, 2013)	0.39
"5 mg dosed every 8, 12, and 24 hours) showed that a pharmacodynamic effect (delta SET ≥20 milliseconds) could be maintained in the absence of excessive omecamtiv mecarbil plasma concentrations."	( Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. Chow, AT; Ma, P; Malik, FI; Vu, T; Wang, YM; Xiao, JJ, 2015)	0.86
" This study will provide essential dosing information for the requisite phase III trials which will investigate whether the beneficial effects of omecamtiv mecarbil translate into improved clinical outcomes."	( Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Dorhout, B; Liu, LC; Teerlink, JR; van der Meer, P; Voors, AA, 2016)	2.08
"Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter."	( Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Adams, KF; Cleland, JG; Ezekowitz, JA; Felker, GM; Goudev, A; Honarpour, N; Johnston, J; Macdonald, P; Malik, FI; McMurray, JJ; Metra, M; Mitrovic, V; Monsalvo, ML; Ponikowski, P; Serpytis, P; Solomon, SD; Spinar, J; Teerlink, JR; Tomcsányi, J; Vandekerckhove, HJ; Voors, AA, 2016)	1.88
" Blood samples were collected up to 144 hours after dosing following administration of OM on days 1 and 9 to characterize plasma concentrations of OM."	( Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects. Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Sohn, W; Terminello, B; Trivedi, A; Zhang, H, 2022)	0.98
"OM showed consistent and predictable pharmacokinetics after multiple dosing in Japanese subjects."	( Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects. Abbasi, S; Aoki, M; Dutta, S; Hutton, S; Lee, E; Mackowski, M; Malik, FI; Trivedi, A, 2021)	0.86

Class	Description
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	6.6610	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259256
G	Vesicular stomatitis virus	Potency	15.0916	0.0123	8.9648	39.8107	AID1645842
Interferon beta	Homo sapiens (human)	Potency	15.0916	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	15.0916	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	15.0916	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	15.0916	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 1A2	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0001	1.7740	10.0000	AID605254
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (112)

Assay ID	Title	Year	Journal	Article
AID1452489	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-systolic pressure at 16 ug/kg/min (Rvb = 87.48 to 97.85 mmHg)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1402191	Positive inotropic activity in Sprague-Dawley rat ventricular myocytes assessed as change in ventricular cell contractility by measuring cell shortening at 1 uM	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator.
AID1452486	Positive inotropic activity in Sprague-Dawley rat heart assessed as fractional shortening at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 38.60 to 55.81%)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID605332	Volume of distribution in Beagle dog heart failure model	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1452483	Positive inotropic activity in Sprague-Dawley rat heart assessed as ejection fraction at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 67.16 to 85.81%)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1577036	Activation of bovine cardiac actin thin filament complex-stimulated myosin S1 ATPase activity assessed as inorganic phosphate liberated at 10 uM incubated for 10 mins in presence of ATP by spectrophotometry relative to control	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
AID605333	Bioavailability in Beagle dog heart failure model	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1577035	Activation of rabbit skeletal muscle actin thin filament complex-stimulated myosin S1 ATPase activity assessed as inorganic phosphate liberated at 100 uM incubated for 10 mins in presence of ATP by spectrophotometry relative to control	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
AID1498822	Activation of actin-stimulated bovine cardiac myosin S1 fragment ATPase activity in sarcomere at 10 uM after 10 mins by spectrophotometric analysis relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator.
AID605247	Induction of contractility in Sprague-Dawley rat Cardiomyocytes assessed as change in fractional shortening at 0.2 uM	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID605244	Solubility of the compound at pH 5 by shake flask method	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1452469	Positive inotropic activity in Sprague-Dawley rat heart assessed as heart rate at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 281 to 347 bpm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452474	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end diastole at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 5.66 to 7.80 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452488	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-systolic pressure at 8 ug/kg/min (Rvb = 87.48 to 97.85 mmHg)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID605334	Bioavailability in Sprague-Dawley rat	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID605254	Inhibition of CYP1A2	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1452468	Positive inotropic activity in Sprague-Dawley rat heart assessed as heart rate at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 281 to 347 bpm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452498	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT max at 8 ug/kg/min (Rvb = 4162 to 5214 mmHg/s)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1402184	Activation of actin-stimulated bovine cardiac myosin S1 fragment ATPase activity in sarcomere at 10 uM after 10 mins by spectrophotometric analysis relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator.
AID1452487	Positive inotropic activity in Sprague-Dawley rat heart assessed as fractional shortening at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 38.60 to 55.81%)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452494	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-diastolic pressure at 16 ug/kg/min (Rvb = 7.68 to 9.64 mmHg)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452504	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT min at 16 ug/kg/min (Rvb = -5462 to -4611 mmHg/s)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452477	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end systole at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.07 to 2.46 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1498823	Activation of actin-stimulated bovine cardiac myosin S1 fragment ATPase activity in sarcomere at 5 uM after 10 mins by spectrophotometric analysis relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator.
AID1452514	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-diastolic pressure at 2 ug/kg/min (Rvb = 7.68 mmHg)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID605255	Ratio of extraction in human Liver microsomes	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1452519	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT min at 4 ug/kg/min (Rvb = -5462 to -4898 mmHg/s)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1242379	Positive inotropic effect in Sprague-Dawley rat ventricular myocytes assessed as change in ventricular cell contractility at 400 nM by video edge detector relative to control	2015	ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7	Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction.
AID1452480	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end diastole at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 0.88 to 1.54 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452503	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT min at 8 ug/kg/min (Rvb = -5462 to -4611 mmHg/s)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1402188	Positive inotropic activity in Sprague-Dawley rat heart assessed as increase in ejection fraction at 2 to 16 ug/kg/min infused for 3 mins by echocardiographic analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator.
AID605331	Volume of distribution in Sprague-Dawley rat	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1498825	Activation of actin-stimulated bovine cardiac myosin S1 fragment ATPase activity in sarcomere after 10 mins by spectrophotometric analysis	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator.
AID1452485	Positive inotropic activity in Sprague-Dawley rat heart assessed as ejection fraction at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 67.16 to 85.81%)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452462	Activation of actin-stimulated bovine cardiac myosin S1 fragment ATPase activity in sarcomere at 10 uM after 10 mins by spectrophotometric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1577033	Positive ionotropic activity in Sprague-Dawley rat assessed as increase in ejection fraction at 16 ug/kg/min, iv for 3 mins by echocardiography relative to control	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
AID1242380	Positive inotropic effect in Sprague-Dawley rat ventricular myocytes assessed as change in ventricular cell contractility at 1 uM by video edge detector relative to control	2015	ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7	Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction.
AID1452464	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricle fractional shortening at 2 to 16 ug/kg/min for 3 mins by echocardiographic analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452493	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-diastolic pressure at 8 ug/kg/min (Rvb = 7.68 to 9.83 mmHg)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1577034	Positive ionotropic activity in Sprague-Dawley rat assessed as increase in fractional shortening at 16 ug/kg/min, iv for 3 mins by echocardiography relative to control	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
AID1452476	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end diastole at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 5.66 to 7.80 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452521	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as heart rate at 4 ug/kg/min (Rvb = 260 to 322 bpm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID605329	Clearance in Sprague-Dawley rat	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1452465	Positive inotropic activity in Sprague-Dawley rat heart assessed as ejection fraction at 2 to 16 ug/kg/min for 3 mins by echocardiographic analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID605328	Inhibition of vasodilation in Sprague-Dawley rat aortic ring	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1452520	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as heart rate at 2 ug/kg/min (Rvb = 322 bpm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452461	Positive inotropic activity in Sprague-Dawley rat heart assessed as fractional shortening at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 38.60 to 55.81%)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452508	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as heart rate at 8 ug/kg/min (Rvb = 260 to 322 bpm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452513	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-systolic pressure at 4 ug/kg/min (Rvb = 94.65 to 97.85 mmHg)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452516	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT max at 2 ug/kg/min (Rvb = 5214 mmHg/s)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1577038	Activation of chicken gizzard muscle actin and tropomyosin-stimulated myosin S1 ATPase activity assessed as inorganic phosphate liberated at 100 uM incubated for 10 mins in presence of ATP by spectrophotometry relative to control	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
AID605327	Activation of Sprague-Dawley rat myosin in cardiomyocytes assessed as compound concentration resulting in 40% increase in ATPase activity at calcium concentrations that produced 25-50% of maximum calcium dependent activation	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1452472	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end systole at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.50 to 4.78 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452466	Activation of actin-stimulated rabbit psoas skeletal muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID605245	Plasma protein binding in Sprague-Dawley rat	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1452460	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-systolic pressure at 2 ug/kg/min (Rvb = 97.85 mmHg)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452484	Positive inotropic activity in Sprague-Dawley rat heart assessed as ejection fraction at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 67.16 to 85.81%)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452515	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-diastolic pressure at 4 ug/kg/min (Rvb = 7.68 to 9.83 mmHg)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1402187	Positive inotropic activity in Sprague-Dawley rat heart assessed as increase in left ventricle fractional shortening at 2 to 16 ug/kg/min infused for 3 mins by echocardiographic analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator.
AID1452509	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as heart rate at 16 ug/kg/min (Rvb = 274 to 322 bpm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452517	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT max at 4 ug/kg/min (Rvb = 4985 to 5214 mmHg/s)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452479	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end systole at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.07 to 2.46 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452471	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end systole at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.50 to 4.78 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1498827	Activation of actin-stimulated chicken gizzard smooth muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator.
AID1452470	Positive inotropic activity in Sprague-Dawley rat heart assessed as heart rate at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 281 to 347 bpm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1577037	Activation of myosin ATPase activity in Sprague-Dawley rat ventricular myocytes assessed as increase in ventricular cell shortening by measuring change in ventricular cell contractility at 1 uM by electrophysiology relative to control	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
AID1498826	Activation of actin-stimulated rabbit psoas skeletal muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator.
AID1452475	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end diastole at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 5.66 to 7.80 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452499	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT max at 16 ug/kg/min (Rvb = 4162 to 5214 mmHg/s)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452481	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end diastole at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 0.88 to 1.54 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452473	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end systole at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.50 to 4.78 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1498824	Activation of actin-stimulated bovine cardiac myosin S1 fragment ATPase activity in sarcomere at 1 uM after 10 mins by spectrophotometric analysis relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator.
AID1402185	Activation of actin-stimulated rabbit skeletal muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator.
AID605330	Clearance in Beagle dog heart failure model	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
AID1402186	Activation of actin-stimulated chicken gizzard smooth muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator.
AID1452482	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end diastole at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 0.88 to 1.54 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1242381	Activation of cardiac myosin S1 ATPase in bovine sarcomere at 10 uM by spectrophometric analysis in presence of actin thin filament complex relative to control	2015	ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7	Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction.
AID1452478	Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end systole at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.07 to 2.46 mm)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452467	Activation of actin-stimulated chicken gizzard smooth muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452518	Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT min at 2 ug/kg/min (Rvb = -5462 mmHg/s)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (1.33)	29.6817
2010's	69 (46.00)	24.3611
2020's	79 (52.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	24 (15.79%)	5.53%
Reviews	26 (17.11%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	102 (67.11%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
nitroxyl nitroxyl: hydroxamic acid oxidized to nitroxyl free radical. nitroxyl : A nitrogen oxoacid consisting of an oxygen atom double-bonded to an NH group.	2.21	1	0	nitrogen oxoacid
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	4.78	4	0	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	17.67	127	24	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	7.41	1	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.21	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.52	2	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	7.31	1	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	3.15	1	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	3.18	1	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	7.41	1	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.21	1	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
vesnarinone [no description available]	3.14	1	0	organic molecular entity
etiocholanolone Etiocholanolone: The 5-beta-reduced isomer of ANDROSTERONE. Etiocholanolone is a major metabolite of TESTOSTERONE and ANDROSTENEDIONE in many mammalian species including humans. It is excreted in the URINE.. 3alpha-hydroxy-5beta-androstan-17-one : An androstanoid that is 5beta-androstane substituted by an alpha-hydroxy group at position 3 and an oxo group at position 17. It is a metabolite of testosterone in mammals.	3.55	2	0	17-oxo steroid; 3alpha-hydroxy steroid; androstanoid	human metabolite; mouse metabolite
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	3.02	4	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
tecnazene tetrachloronitrobenzene: sprout suppressant for potatoes; can be either the 1,2,4,5- and/or the 1,2,3,5-tetrachloro isomer; RN given refers to cpd with unspecified isomeric designation. tecnazene : A C-nitro compound that is nitrobenzene in which the four hydrogens located ortho- and para- to the nitro group have been replaced by chlorines. A fungicide used to control dry rot, it is no longer approved for use within the European Union.	2.21	1	0	aromatic fungicide; C-nitro compound; tetrachlorobenzene	antifungal agrochemical
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	3.14	1	0	diazine; pyrazines	Daphnia magna metabolite
monocrotaline Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.	3.7	1	1	pyrrolizidine alkaloid
cadmium chloride Cadmium Chloride: A cadmium halide in the form of colorless crystals, soluble in water, methanol, and ethanol. It is used in photography, in dyeing, and calico printing, and as a solution to precipitate sulfides. (McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). cadmium dichloride : A cadmium coordination entity in which cadmium(2+) and Cl(-) ions are present in the ratio 2:1. Although considered to be ionic, it has considerable covalent character to its bonding.	3.7	1	1	cadmium coordination entity
dobutamine Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.	4.59	7	0	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
fura-2 Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.	2.25	1	0
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	4.87	3	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
simendan Simendan: A hydrazone and pyridazine derivative; the levo-form is a phosphodiesterase III inhibitor, calcium-sensitizing agent, and inotropic agent that is used in the treatment of HEART FAILURE.	4.96	6	0
rolofylline rolofylline: selective antagonist for adenosine receptors; a cardiovascular agent	3.18	1	0	oxopurine
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	4.19	2	0	D-glucopyranose	epitope; mouse metabolite
fura-2-am fura-2-am: pentaester precursor of fura-2	2.25	1	0
ivabradine Ivabradine: A benzazepine derivative and selective HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS inhibitor that lowers the heart rate. It is used in the treatment of CHRONIC STABLE ANGINA in patients unable to take BETA-ADRENERGIC BLOCKERS, and in the treatment of HEART FAILURE.. ivabradine : A member of the class of benzazepines that is 7,8-dimethoxy-1,3,4,5-tetrahydro-3-benzazepin-2-one in which the amide hydrogen is replaced by a [{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl} group. Used (as its hydrochloride salt) to treat patients with angina who have intolerance to beta blockers and/or heart failure.	9.48	3	0	aromatic ether; benzazepine; carbobicyclic compound; tertiary amino compound	cardiotonic drug
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	3.8	1	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
clevidipine clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source	3.15	1	0	dihydropyridine
chrysosplenol c chrysosplenol C: isolated from Pterocaulon sphacelatum; structure in first source. chrysosplenol C : A trimethoxyflavone that is the 3,7,3'-trimethyl ether derivative of quercetagetin.	2.11	1	0	trihydroxyflavone; trimethoxyflavone	antineoplastic agent; antiviral agent; plant metabolite
glycosides [no description available]	2.31	1	0
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	6.65	5	1	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
blister blebbistatin: structure in first source. blebbistatin : A pyrroloquinoline that is 1,2,3,3a-tetrahydro-H-pyrrolo[2,3-b]quinolin-4-one substituted by a hydroxy group at position 3a, a methyl group at position 6 and a phenyl group at position 1. It acts as an inhibitor of ATPase activity of non-muscle myosin II.	2.17	1	0	cyclic ketone; pyrroloquinoline; tertiary alcohol; tertiary alpha-hydroxy ketone	inhibitor
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	2.31	1	0	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
blebbistatin (S)-blebbistatin : The (S)-enantiomer of blebbistatin.	3.09	4	0	blebbistatin; tertiary alpha-hydroxy ketone
artemetin [no description available]	2.11	1	0	ether; flavonoids
fumarates Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)	3.19	1	0	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
aliskiren aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.	3.19	1	0	monocarboxylic acid amide; monomethoxybenzene	antihypertensive agent
bay 58-2667 BAY 58-2667: activates guanylyl cyclase; structure in first source. cinaciguat : A benzoic acid that is 4-(aminomethyl)benzoic acid in which the amino group is substituted by 4-carboxybutyl and 2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl groups. It is a soluble guanylate cyclase activator, used for the treatment of acute decompensated heart failure.	3.19	1	0	aromatic ether; benzoic acids; dicarboxylic acid; tertiary amino compound	antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent
istaroxime Istaroxime: PST-2744 is the (E,Z)-isomer; a positive cardiac inotropic agent; structure in first source	3.55	2	0
rivaroxaban Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.	2.21	1	0	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
acebutolol alpha-D-glucosyl-(1->4)-alpha-D-mannose : An alpha-D-glucosyl-(1->4)-D-mannopyranose in which the anomeric hydroxy group has alpha configuration.	3.82	2	0	alpha-D-glucosyl-(1->4)-D-mannopyranose
bay 63-2521 riociguat: guanylate cyclase stimulator; structure in first source. riociguat : A carbamate ester that is the methyl ester of {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamic acid. It is used for treatment of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension	3.31	1	0	aminopyrimidine; carbamate ester; organofluorine compound; pyrazolopyridine	antihypertensive agent; soluble guanylate cyclase activator
empagliflozin [no description available]	4.19	2	0	aromatic ether; C-glycosyl compound; monochlorobenzenes; tetrahydrofuryl ether	hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor
atrial natriuretic factor Atrial Natriuretic Factor: A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS.	4.1	2	0	polypeptide
ularitide Ularitide: a 32-amino acid peptide derived from (95-126 residues) of ANP PROHORMONE (1-126 residues); not biologically inactivated by a peptidase from dog kidney cortex membranes	4.1	2	0
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	8.35	10	2
natriuretic peptide, brain Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.	7.71	5	2	polypeptide
vericiguat vericiguat: a guanylate cyclase stimulator; FDA approved for the treatment of chronic heart failure.. vericiguat : A pyrazolopyridine that is 5-fluoro-1H-pyrazolo[3,4-b]pyridine in which the amino hydrogen at position 1 has been substituted by a 2-fluorobenzyl group and the hydrogen at position 3 has been substituted by a 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl group. It is a soluble guanylate cyclase stimulator which is used for treatment of chronic heart failure.	4.33	2	0	aminopyrimidine; carbamate ester; organofluorine compound; pyrazolopyridine	antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent
adrenomedullin Adrenomedullin: A 52-amino acid peptide with multi-functions. It was originally isolated from PHEOCHROMOCYTOMA and ADRENAL MEDULLA but is widely distributed throughout the body including lung and kidney tissues. Besides controlling fluid-electrolyte homeostasis, adrenomedullin is a potent vasodilator and can inhibit pituitary ACTH secretion.	3.18	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	3.19	1	0
ferric carboxymaltose ferric carboxymaltose: effective for treatment of postpartum anemia	3.82	2	0

Condition	Indicated	Relationship Strength	Studies	Trials
Systolic Heart Failure [description not available]	0	11.79	26	5
Heart Failure, Systolic Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.	0	11.79	26	5
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	5.64	11	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Fish Diseases Diseases of freshwater, marine, hatchery or aquarium fish. This term includes diseases of both teleosts (true fish) and elasmobranchs (sharks, rays and skates).	0	3.7	1	1
Cardiac Failure [description not available]	0	16.21	67	19
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	1	18.21	67	19
Ventricular Dysfunction A condition in which HEART VENTRICLES exhibit impaired function.	0	2.41	1	0
Asystole [description not available]	0	2.41	1	0
Nervous System Disorders [description not available]	0	2.41	1	0
Heart Arrest Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.	0	2.41	1	0
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	0	2.41	1	0
Auricular Fibrillation [description not available]	0	8.29	13	2
Auricular Flutter [description not available]	0	4.72	1	1
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	0	8.29	13	2
Atrial Flutter Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).	0	4.72	1	1
Left Ventricular Dysfunction [description not available]	0	9.14	8	4
Ventricular Dysfunction, Left A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.	0	9.14	8	4
Chronic Illness [description not available]	0	6.5	4	2
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	6.5	4	2
Aortic Incompetence [description not available]	0	2.96	3	0
Aortic Valve Insufficiency Pathological condition characterized by the backflow of blood from the ASCENDING AORTA back into the LEFT VENTRICLE, leading to regurgitation. It is caused by diseases of the AORTIC VALVE or its surrounding tissue (aortic root).	0	2.96	3	0
Blood Pressure, Low [description not available]	0	2.41	1	0
Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.	0	7.41	1	0
Arrhythmia [description not available]	0	2.82	2	0
Cardiomyopathies, Primary [description not available]	0	2.61	2	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	0	2.82	2	0
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	0	2.61	2	0
Apoplexy [description not available]	0	3.64	2	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	3.64	2	0
Cardiomyopathy, Congestive [description not available]	0	3.77	3	0
Cardiomyopathy, Dilated A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.	0	3.77	3	0
Heart Disease, Ischemic [description not available]	0	5.16	3	1
Acute Disease Disease having a short and relatively severe course.	0	7.3	8	1
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	0	5.16	3	1
Adult Onset Nemaline Myopathy [description not available]	0	2.21	1	0
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	0	3.74	3	0
Myopathies, Nemaline A group of inherited congenital myopathic conditions characterized clinically by weakness, hypotonia, and prominent hypoplasia of proximal muscles including the face. Muscle biopsy reveals large numbers of rod-shaped structures beneath the muscle fiber plasma membrane. This disorder is genetically heterogeneous and may occasionally present in adults. (Adams et al., Principles of Neurology, 6th ed, p1453)	0	2.21	1	0
Anemias, Iron-Deficiency [description not available]	0	2.21	1	0
Blood Pressure, High [description not available]	0	2.21	1	0
Cardiovascular Stroke [description not available]	0	2.8	3	0
Blood Clot [description not available]	0	2.21	1	0
Cardiac Aneurysm [description not available]	0	2.21	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	2.21	1	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	2.8	3	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	0	2.21	1	0
Anemia, Iron-Deficiency Anemia characterized by decreased or absent iron stores, low serum iron concentration, low transferrin saturation, and low hemoglobin concentration or hematocrit value. The erythrocytes are hypochromic and microcytic and the iron binding capacity is increased.	0	2.21	1	0
Cardiac Remodeling, Ventricular [description not available]	0	8.96	8	2
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	8.73	5	4
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	0	2.31	1	0
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	0	2.31	1	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	2.31	1	0
Muscle Pain [description not available]	0	3.7	1	1
Myalgia Painful sensation in the muscles.	0	3.7	1	1
Shock, Cardiogenic Shock resulting from diminution of cardiac output in heart disease.	0	2.21	1	0
Cardiomyopathy, Hypertrophic Obstructive [description not available]	0	3.12	1	0
Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).	0	3.12	1	0
Hyperpotassemia [description not available]	0	3.12	1	0
Hyperkalemia Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)	0	3.12	1	0
Breathlessness [description not available]	0	3.42	2	0
Dyspnea Difficult or labored breathing.	0	3.42	2	0
Left Ventricular Hypertrophy [description not available]	0	3.01	1	0
Hypertrophy, Left Ventricular Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.	0	3.01	1	0
Angor Pectoris [description not available]	0	4.41	1	1
Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.	0	4.41	1	1
Deaf Mutism [description not available]	0	2.11	1	0
Deafness A general term for the complete loss of the ability to hear from both ears.	0	2.11	1	0
Dizzyness [description not available]	0	2.13	1	0
Anasarca [description not available]	0	2.13	1	0
Lassitude [description not available]	0	2.13	1	0
Chronic Insomnia [description not available]	0	2.13	1	0
Dizziness An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.	0	2.13	1	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	0	2.13	1	0
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	0	2.13	1	0
Sleep Initiation and Maintenance Disorders Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.	0	2.13	1	0

omecamtiv mecarbil

Cross-References

Synonyms (62)

Research Excerpts

Overview

Effects

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (7)

Potency Measurements

Inhibition Measurements

Biological Processes (69)

Molecular Functions (31)

Ceullar Components (24)

Bioassays (112)

Research

Studies (150)

Market Indicators

Research Demand Index: 53.06

Study Types

omecamtiv mecarbil

Cross-References

Synonyms (62)

Research Excerpts

Overview

Effects

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (7)

Potency Measurements

Inhibition Measurements

Biological Processes (69)

Molecular Functions (31)

Ceullar Components (24)

Bioassays (112)

Research

Studies (150)

Market Indicators

Research Demand Index: 53.06

Study Types

Related Drugs (51)

Related Conditions (76)